MX2021013338A - Método para tratar la tos usando un compuesto de diaminopirimidina. - Google Patents
Método para tratar la tos usando un compuesto de diaminopirimidina.Info
- Publication number
- MX2021013338A MX2021013338A MX2021013338A MX2021013338A MX2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A MX 2021013338 A MX2021013338 A MX 2021013338A
- Authority
- MX
- Mexico
- Prior art keywords
- diaminopyrimidine compound
- treating cough
- cough
- compound
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019085180 | 2019-04-30 | ||
| PCT/CN2020/087686 WO2020221274A1 (zh) | 2019-04-30 | 2020-04-29 | 二氨基嘧啶类化合物治疗咳嗽的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013338A true MX2021013338A (es) | 2022-01-24 |
Family
ID=73029672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013338A MX2021013338A (es) | 2019-04-30 | 2020-04-29 | Método para tratar la tos usando un compuesto de diaminopirimidina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220211703A1 (enExample) |
| EP (1) | EP3960179B1 (enExample) |
| JP (1) | JP7665529B2 (enExample) |
| KR (1) | KR102935436B1 (enExample) |
| CN (1) | CN114007619B (enExample) |
| AU (1) | AU2020265327B2 (enExample) |
| BR (1) | BR112021021600A2 (enExample) |
| MX (1) | MX2021013338A (enExample) |
| SG (1) | SG11202111877TA (enExample) |
| TW (1) | TWI736243B (enExample) |
| WO (1) | WO2020221274A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117186068A (zh) * | 2017-11-01 | 2023-12-08 | 北京泰德制药股份有限公司 | P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2557372C (en) * | 2004-03-05 | 2013-01-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| EP1924564B1 (en) * | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| AU2007304280B2 (en) | 2006-10-04 | 2013-01-31 | F. Hoffmann-La Roche Ag | Process for synthesis of phenoxy diaminopyrimidine derivatives |
| AU2014308606B2 (en) * | 2013-08-23 | 2017-08-03 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine P2X3 and P2X 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
| DK3355889T3 (da) * | 2015-09-29 | 2023-05-15 | Afferent Pharmaceuticals Inc | Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste |
| WO2017160569A1 (en) * | 2016-03-14 | 2017-09-21 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| AU2017237929B2 (en) * | 2016-03-25 | 2021-04-15 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| CN117186068A (zh) * | 2017-11-01 | 2023-12-08 | 北京泰德制药股份有限公司 | P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途 |
-
2020
- 2020-04-29 BR BR112021021600A patent/BR112021021600A2/pt unknown
- 2020-04-29 EP EP20799419.5A patent/EP3960179B1/en active Active
- 2020-04-29 JP JP2021564189A patent/JP7665529B2/ja active Active
- 2020-04-29 CN CN202080032489.4A patent/CN114007619B/zh active Active
- 2020-04-29 KR KR1020217038551A patent/KR102935436B1/ko active Active
- 2020-04-29 MX MX2021013338A patent/MX2021013338A/es unknown
- 2020-04-29 WO PCT/CN2020/087686 patent/WO2020221274A1/zh not_active Ceased
- 2020-04-29 US US17/607,438 patent/US20220211703A1/en active Pending
- 2020-04-29 SG SG11202111877TA patent/SG11202111877TA/en unknown
- 2020-04-29 AU AU2020265327A patent/AU2020265327B2/en active Active
- 2020-04-30 TW TW109114696A patent/TWI736243B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3960179B1 (en) | 2026-03-18 |
| WO2020221274A1 (zh) | 2020-11-05 |
| CN114007619A (zh) | 2022-02-01 |
| SG11202111877TA (en) | 2021-11-29 |
| BR112021021600A2 (pt) | 2022-01-04 |
| CA3138780A1 (en) | 2020-11-05 |
| US20220211703A1 (en) | 2022-07-07 |
| TWI736243B (zh) | 2021-08-11 |
| CN114007619B (zh) | 2024-08-06 |
| JP7665529B2 (ja) | 2025-04-21 |
| AU2020265327A1 (en) | 2021-12-16 |
| JP2022530890A (ja) | 2022-07-04 |
| EP3960179A4 (en) | 2023-01-25 |
| EP3960179A1 (en) | 2022-03-02 |
| KR102935436B1 (ko) | 2026-03-05 |
| KR20220007620A (ko) | 2022-01-18 |
| AU2020265327B2 (en) | 2025-09-11 |
| TW202106302A (zh) | 2021-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551585A1 (en) | Substituted tricyclic compounds | |
| NZ756231A (en) | A novel isoindoline derivative, a pharmaceutical composition and use thereof | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| PH12021551844A1 (en) | INVENTION-JAK Inhibitor And Preparation Method Thereof | |
| SA518391836B1 (ar) | تيتراهيدروبيرانيل أمينو-بيرولوبيريميدينون وطرق استخدامه | |
| BR112021026214A2 (pt) | Método para tratamento de fibrose pulmonar idiopática | |
| MX2017010477A (es) | Compuestos triciclicos y usos de los mismos en medicina. | |
| MY209754A (en) | Amide derivative and preparation method therefore and use thereof in medicine | |
| MX2010001189A (es) | Derivados de naftiridina como modulares del canal de potasio. | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| EP4592275A3 (en) | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | |
| PH12018500777A1 (en) | Farnesoid x receptor modulators | |
| TN2016000581A1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| AU2015293541B2 (en) | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof | |
| IN2014KN00948A (enExample) | ||
| MX2023012743A (es) | Derivado de fosfonilo, y composición y aplicación farmacéutica de éste. | |
| EP4582424A3 (en) | 1,2-naphthoquinone derivative and method for preparing same | |
| MY196788A (en) | Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof | |
| MY194087A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
| WO2016085939A3 (en) | Compounds and methods of treating ocular disorders | |
| PH12022551523A1 (en) | Cyclic compounds and methods of using same | |
| MX336505B (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
| NZ721645A (en) | Compounds for use as gpr120 agonists |